Vaccine News and Research

Latest Vaccine News and Research

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

New breakthrough: Seaweed for treatment of swine flu

In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.

5 May 2010

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Boehringer Ingelheim and Micromet, Inc. announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

5 May 2010

Older men who receive pneumococcal vaccine not less likely to have heart attack, stroke: JAMA

Men 45 years or older who received pneumococcal vaccine were not less likely to have a heart attack or stroke compared to men who did not receive the vaccine, according to a study in the May 5 issue of JAMA.

5 May 2010

Cryo-EM images shed light on virus structure, function

UCLA researchers report in the April 30 edition of the journal Cell that they have imaged a virus structure at a resolution high enough to effectively "see" atoms, the first published instance of imaging biological complexes at such a resolution.

5 May 2010

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Vical Incorporated today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin®-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC).

5 May 2010

Archivel Farma to start phase II clinical trials of RUTI vaccine for Latent Tuberculosis

Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.

5 May 2010

Abbott announces opening of Asia-Pacific Nutrition R&D Center

Abbott, the global health care company, today announced the opening of the Abbott Asia-Pacific Nutrition Research & Development Center at Singapore's Biopolis Research Park. The center is Abbott's largest nutrition R&D facility outside of the U.S., and Singapore's first nutrition R&D site creating science-based nutritional products for infants, children and adults.

5 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Widespread support for a full flu vaccine side effects enquiry

After nearly 250 children suffered from serious side effects of the seasonal flu shots including one death the Western Australian Government’s step to suspend further vaccinations and investigate the issue has received widespread support. The enquiry will look into the Health Department's handling of the flu vaccination program as well.

4 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Each day in the United States, 482 people are diagnosed with a brain tumor. For these 482 people, not many treatments exist. With the current treatments available, only 5% of those diagnosed with a Glioblastoma Multiform will survive more than 5 years. Only two new treatments have been approved by the FDA in the past two decades.

4 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

MicroStockProfit.com releases investment report on Vical

MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

GlycoVaxyn AG, a leader in the development of innovative bioconjugate vaccines, and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, announced today that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine. S. aureus is a major cause of hospital-based infections.

4 May 2010

National Cancer Institute data: San Francisco has highest rate of liver cancer in the nation

Recent data released from the National Cancer Institute confirms that San Francisco has the highest rate of liver cancer in the nation. The leading cause of liver cancer is hepatitis B.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Lung researchers at Johns Hopkins have identified a possible protein trigger responsible for sarcoidosis, a potentially fatal inflammatory disease marked by tiny clumps of inflammatory cells that each year leave deep, grainy scars on the lungs, lymph nodes, skin and almost all major organs in hundreds of thousands of Americans.

4 May 2010

H1N1 positivity highest among children

More than 99 percent of specimens tested for influenza were positive for H1N1 over approximately the past 11 months, according to a report released today from Quest Diagnostics Incorporated ( DGX). The Quest Diagnostics Health Trends™ Report suggests that H1N1 "crowded out" other influenza viruses to be the dominant flu virus of the 2009-2010 flu season.

4 May 2010

Vaccine News and Research

Latest Vaccine News and Research

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

New breakthrough: Seaweed for treatment of swine flu

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Older men who receive pneumococcal vaccine not less likely to have heart attack, stroke: JAMA

Cryo-EM images shed light on virus structure, function

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Archivel Farma to start phase II clinical trials of RUTI vaccine for Latent Tuberculosis

Abbott announces opening of Asia-Pacific Nutrition R&D Center

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Widespread support for a full flu vaccine side effects enquiry

Celldex reports net loss of $6.6 million for first-quarter 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

MicroStockProfit.com releases investment report on Vical

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

National Cancer Institute data: San Francisco has highest rate of liver cancer in the nation

Novel combined immunotherapy promising for treatment of malignant brain tumors

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

H1N1 positivity highest among children

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in